Financial Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update byJosh SandbergNovember 7, 2019
Biologics Spine Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure byJosh SandbergJune 13, 2019
Biologics Bone Therapeutics announces single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis byJosh SandbergOctober 17, 2018
Biologics Bone Therapeutics SA announces final results from Phase I/IIA ALLOB delayed-union fracture study byJosh SandbergSeptember 14, 2018
